Learn more about customized services for your metabolic drug or device clinical development programs.

contact us

Learn more about patient screening strategies for NASH clinical research.

NASH patient access

Patient Access and Subject Enrollment

ProSciento is a recognized leader in deploying patient access and subject enrollment for metabolic clinical trials. Core to our success in this area are our advanced pre-screening and retention strategies.

For multinational trials, we offer a top-tier network of metabolic sites in key geographic areas with access to >1 million active study participants.

For trials conducted at ProSciento’s dedicated clinical research unit (CRU) in southern California, we have an expert on-site recruitment team and a proprietary database of >30,000 active study participants.